PE20230493A1 - Vacuna contra hpv - Google Patents

Vacuna contra hpv

Info

Publication number
PE20230493A1
PE20230493A1 PE2022001736A PE2022001736A PE20230493A1 PE 20230493 A1 PE20230493 A1 PE 20230493A1 PE 2022001736 A PE2022001736 A PE 2022001736A PE 2022001736 A PE2022001736 A PE 2022001736A PE 20230493 A1 PE20230493 A1 PE 20230493A1
Authority
PE
Peru
Prior art keywords
hpv
hpv vaccine
virus
vaccine
vlps
Prior art date
Application number
PE2022001736A
Other languages
English (en)
Inventor
Marian E Gindy
John P Bilello
Amy S Espeseth
Andrew J Bett
Tong-Ming Fu
Original Assignee
Merck Sharp And Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp And Dohme Llc filed Critical Merck Sharp And Dohme Llc
Publication of PE20230493A1 publication Critical patent/PE20230493A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgacion proporciona, entre otras cosas, una composicion farmaceutica que incluye un adyuvante de nanoparticulas lipidicas y una vacuna contra el virus del papiloma humano (HPV) que comprende particulas similares a virus (VLP) de HPV de al menos un tipo de virus del papiloma humano (HPV) seleccionado del grupo que consiste en los tipos de HPV: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73 y 82
PE2022001736A 2020-02-14 2021-02-09 Vacuna contra hpv PE20230493A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062976673P 2020-02-14 2020-02-14
PCT/US2021/017157 WO2021163002A1 (en) 2020-02-14 2021-02-09 Hpv vaccine

Publications (1)

Publication Number Publication Date
PE20230493A1 true PE20230493A1 (es) 2023-03-23

Family

ID=74853762

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001736A PE20230493A1 (es) 2020-02-14 2021-02-09 Vacuna contra hpv

Country Status (20)

Country Link
US (3) US11638754B2 (es)
EP (1) EP4103227A1 (es)
JP (1) JP2023516904A (es)
KR (1) KR20220140901A (es)
CN (1) CN115103687A (es)
AR (1) AR121292A1 (es)
AU (1) AU2021219652A1 (es)
BR (1) BR112022015313A2 (es)
CA (1) CA3166256A1 (es)
CL (1) CL2022002167A1 (es)
CO (1) CO2022011392A2 (es)
CR (1) CR20220395A (es)
DO (1) DOP2022000168A (es)
EC (1) ECSP22063122A (es)
IL (1) IL295234A (es)
JO (1) JOP20220187A1 (es)
MX (1) MX2022009964A (es)
PE (1) PE20230493A1 (es)
TW (1) TW202140069A (es)
WO (1) WO2021163002A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023023152A1 (en) * 2021-08-19 2023-02-23 Merck Sharp & Dohme Llc Thermostable lipid nanoparticle and methods of use thereof
CN115850686A (zh) * 2021-09-27 2023-03-28 广州谷森制药有限公司 新型氘代peg脂质化合物、其制备方法、组合物和应用
US11951177B2 (en) * 2022-03-23 2024-04-09 Nanovation Therapeutics Inc. High sterol-containing lipid nanoparticles

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
CA2202090C (en) 1994-10-07 2012-04-17 Lutz Gissmann Papilloma virus-like particles, fusion proteins as well as processes for their production
US5820870A (en) 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
EP0910343A1 (en) 1996-07-03 1999-04-28 University Of Pittsburgh Emulsion formulations for hydrophilic active agents
WO2002087541A1 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
US7514099B2 (en) 2005-02-14 2009-04-07 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
PT2311848E (pt) 2002-12-23 2013-10-03 Vical Inc Vacinas à base de polinucleótido optimizadas por codão contra a infecção do citomegalovírus humano
CN100506999C (zh) 2003-03-24 2009-07-01 麦克公司 Hpv31l1在酵母中的优化表达
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
CA2560487C (en) 2004-03-24 2013-01-29 Merck & Co., Inc. Optimized expression of hpv 52 l1 in yeast
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
CA2606092A1 (en) 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2129394B1 (en) * 2007-03-09 2012-06-20 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
US20100055168A1 (en) 2008-04-16 2010-03-04 Abbott Laboratories Cationic lipids and uses thereof
US20090285881A1 (en) 2008-04-16 2009-11-19 Abbott Laboratories Cationic lipids and uses thereof
US20100104629A1 (en) 2008-04-16 2010-04-29 Abbott Laboratories Cationic lipids and uses thereof
US20090263407A1 (en) 2008-04-16 2009-10-22 Abbott Laboratories Cationic Lipids and Uses Thereof
US20100076055A1 (en) 2008-04-16 2010-03-25 Abbott Laboratories Cationic Lipids and Uses Thereof
US20100055169A1 (en) 2008-04-16 2010-03-04 Abbott Laboratories Cationic lipids and uses thereof
WO2009132131A1 (en) 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Amino lipid based improved lipid formulation
EP2326331A4 (en) 2008-08-18 2013-05-15 Merck Sharp & Dohme NOVEL LIPID NANOPARTICLES AND NEW COMPONENTS FOR NUCLEIC ACID ADMINISTRATION
WO2010030739A1 (en) 2008-09-10 2010-03-18 Abbott Laboratories Polyethylene glycol lipid conjugates and uses thereof
US20100099738A1 (en) 2008-09-10 2010-04-22 Abbott Laboratories Polyethylene glycol lipid conjugates and uses thereof
CN104119242B (zh) 2008-10-09 2017-07-07 泰米拉制药公司 改善的氨基脂质和递送核酸的方法
WO2010105209A1 (en) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
US8952955B2 (en) 2009-06-17 2015-02-10 Sharp Kabushiki Kaisha Display driving circuit, display device and display driving method
US9181295B2 (en) 2009-08-20 2015-11-10 Sirna Therapeutics, Inc. Cationic lipids with various head groups for oligonucleotide delivery
CN102905763B (zh) 2009-12-23 2015-06-17 诺华股份有限公司 脂质、脂质组合物和使用它们的方法
ES2384060B1 (es) 2010-03-24 2013-09-23 Lipotec S.A. Cápsulas de nanopartículas lipídicas.
KR101878361B1 (ko) 2010-09-20 2018-08-20 시르나 쎄러퓨틱스 인코퍼레이티드 올리고뉴클레오티드 전달을 위한 신규 저분자량 양이온성 지질
JP6050811B2 (ja) 2011-06-24 2016-12-21 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アルミニウムアジュバントを含むｈｐｖワクチン製剤およびその産生方法
EP3110401A4 (en) * 2014-02-25 2017-10-25 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
EP3364982A4 (en) * 2015-10-22 2019-04-17 ModernaTX, Inc. VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES

Also Published As

Publication number Publication date
DOP2022000168A (es) 2022-09-30
US11638754B2 (en) 2023-05-02
JOP20220187A1 (ar) 2023-01-30
CO2022011392A2 (es) 2022-08-19
WO2021163002A1 (en) 2021-08-19
US20230123584A1 (en) 2023-04-20
US20230270850A1 (en) 2023-08-31
KR20220140901A (ko) 2022-10-18
CR20220395A (es) 2022-10-27
TW202140069A (zh) 2021-11-01
AU2021219652A1 (en) 2022-08-18
JP2023516904A (ja) 2023-04-21
BR112022015313A2 (pt) 2022-09-27
CA3166256A1 (en) 2021-08-19
AR121292A1 (es) 2022-05-04
CN115103687A (zh) 2022-09-23
EP4103227A1 (en) 2022-12-21
IL295234A (en) 2022-10-01
CL2022002167A1 (es) 2023-02-03
US20210252138A1 (en) 2021-08-19
ECSP22063122A (es) 2022-11-30
MX2022009964A (es) 2022-09-19

Similar Documents

Publication Publication Date Title
PE20230493A1 (es) Vacuna contra hpv
Cimica et al. Adjuvant formulations for virus-like particle (VLP) based vaccines
JP2016185988A5 (es)
PE20061287A1 (es) COMPOSICION INMUNOGENICA QUE COMPRENDE gE VZV Y EL ADYUVANTE TH-1
AR077396A2 (es) EXPRESIoN OPTIMIZADA DE LA PROTEíNA DE LA CÁPSIDE L1 DEL VIRUS DE PAPILOMA HUMANO VPH45 EN LEVADURAS
DOP2017000294A (es) Unidad de dosificación orodispersable que contiene un componente estetrol
AR041880A1 (es) Composicion inmunogena
AR106026A1 (es) Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos
CO6480995A2 (es) Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
JP2011225578A5 (es)
PE20151588A1 (es) Vacuna contra el virus del dengue
BR112018011331A2 (pt) mutante de proteìna l1 de papillomavirus humano tipo 11
AR103427A1 (es) Vacuna contra la fiebre aftosa
CA2510457A1 (en) Hpv-16 and -18 l1 vlp vaccine
PE20110327A1 (es) Vacuna contra el virus de papiloma humano
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
CY1113830T1 (el) Εμβολιο εναντι hpv16 και hpv18 και τουλαχιστον ενος αλλου τυπου hpv ο οποιος επιλεγεται απο hpv 31,45 ή 52
PE20230349A1 (es) Vacunas para la papilomatosis respiratoria recurrente y metodos para usar estas
SG153837A1 (en) Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
MX2023012530A (es) Composición y metodos de vacuna adyuvada.
CL2013002723A1 (es) Metodo de produccion de una particula semejante a virus (vlp) de alfavirus salmonido (sav) en celulas de insecto.
MX2022000777A (es) Composicion de inmunogenicidad polivalente para el virus de papiloma humano.
AR041515A1 (es) Vacuna a dna contra el virus de papiloma humano
MX2022004869A (es) Vacuna de particulas similares al virus chikungunya y metodos de uso de la misma.
AR074485A1 (es) Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos